Developer docs
API playgroundTry for free, no card

Search company profiles

Kabafusion, Llc

Full company profile

uuid02l5gsz

Namestring
Kabafusion, Llc
Legal namestring
KabaFusion Holdings, LLC
Websiteurl
kabafusion.com
Company typeenum
Private
Founded yearint
2010
Descriptiontext

KabaFusion, founded in 2010 by Dr. Sohail Masood, is a national provider of home and alternative site infusion therapy services and operates as the largest privately held home infusion company in the United States. The company specializes in intravenous immunoglobulin (IVIG) and subcutaneous immunoglobulin (SCIG) therapies for chronic conditions — including primary immunodeficiency, neuromuscular disorders (CIDP, GBS, MMN, myasthenia gravis), and dermatological diseases — alongside IV antibiotics, antifungals, and parenteral nutrition. Services are delivered through a network of 33 infusion pharmacies and 21 ambulatory infusion suites licensed across 45 states, supported by specially trained infusion nurses and pharmacists providing 24/7 clinical care. The company employs approximately 2,000 people and holds ACHC and URAC accreditations.

The core technology stack centers on a patient-facing mobile application (myKabaFusion) enabling care team communication, electronic document signing, monthly reordering, and planned telehealth and delivery tracking, complemented by telemonitoring for remote patient oversight. In September 2025, KabaFusion added an AI-powered referral management capability via a strategic partnership with Tennr to automate patient onboarding and reduce administrative friction.

KabaFusion generates revenue primarily through insurance reimbursement (Medicare, Medicaid, and commercial payors) for clinical infusion services and the dispensing of specialty infusion medications, with pricing varying by drug, dose, site of administration, and payor mix. The go-to-market model is sales-led and built on physician referrals, accelerated by rapid coverage verification turnaround and dedicated provider support. Following the February 2026 completion of a approximately $2.2 billion growth investment by Nautic Partners (acquiring from Novo Holdings), the clinician-led management team remains significant investors and continues to lead operations, with stated intent to expand market presence across the U.S. healthcare infusion sector.

Short descriptiontext

KabaFusion is a national home and alternative site infusion provider delivering IVIG, SCIG, IV antibiotics, and parenteral nutrition across 45 states through 33 pharmacies and 21 ambulatory infusion suites, serving adult and pediatric patients with chronic immune, neuromuscular, and dermatological conditions.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersLexington, United States
HQ citystring
Lexington
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
home infusion therapy, specialty infusion pharmacy, IVIG infusion services, ambulatory infusion suites, parenteral nutrition therapy
Industry6 codes
PRIMARYHLAFALAG
Infusion & Home Infusion Pharmacy Services
Healthcare & Life Sciences/Healthcare Providers & Systems/Pharmacy & Medication Management Services
SECONDARYHLAFABAF
Infusion Therapy Centers (Outpatient)
Healthcare & Life Sciences/Healthcare Providers & Systems/Ambulatory & Outpatient Care Centers
SECONDARYHLADAFAG
Home Infusion Therapy & IV Nursing Services
Healthcare & Life Sciences/Elder Care & Long-Term Care/Home Health Care Services (Skilled)
SECONDARYHLAFAEAE
Home Infusion Therapy Providers
SECONDARYHSABACAF
IV Therapy, Infusion & Injection Services (Home-Based)
Home & Personal Services/Elder Care & In-Home Care Services/Skilled Nursing & Clinical Home Health
SECONDARYHLAIACAO
Specialty Injectable & Infusion Therapies (Cross-therapeutic)
NAICS code2 codes
  • All Other Outpatient Care Centers621498
  • Other Ambulatory Health Care Services6219
SIC code1 code
  • Services-Specialty Outpatient Facilities, Nec8093
Product category
Home Infusion Therapy Services
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Home Infusion Therapy Services
TypeManaged Services
Description

KabaFusion generates revenue by providing home and alternative site infusion therapies including IVIG, antibiotics, antifungals, parenteral nutrition, and other specialty medications. Services are reimbursed by insurance payors including Medicare, Medicaid, and commercial insurance. The company serves patients across 45 states through its network of infusion pharmacies and ambulatory infusion suites.

kabafusion.com
2Pharmacy Services and Specialty Medications
TypeManaged Services
Description

Compounding and dispensing specialty infusion medications through licensed pharmacies, with reimbursement through pharmacy benefits.

pay.kabafusion.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales
Pricing details1 tier
1Insurance-reimbursed infusion therapy — no publicly listed pricing; costs covered by Medicare, Medicaid, and commercial insurers
ModelOtherBilling cadencePay-as-you-go
Notes

IVIG costs vary by patient weight, brand, site of administration, and treatment duration. Most insurers cover therapy; pre-authorization often required.

kabafusion.com
GTM typeB2C
B2C
Offering typeServices
Services
Core offering1 text field

KabaFusion operates a national specialty infusion pharmacy platform that provides home and ambulatory-site infusion therapies for patients with chronic and acute conditions. The company dispenses and administers IVIG/SCIG, IV antibiotics, parenteral nutrition, and condition-specific treatments for primary immunodeficiency, neuromuscular disorders, and dermatological diseases across 33 infusion pharmacies and 21 ambulatory infusion suites in 45 states.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

KabaFusion is a national provider of home and alternative site infusion therapies offering a comprehensive portfolio of services centered around intravenous immunoglobulin (IVIG) and subcutaneous immunoglobulin (SCIG) treatments. The company's core offerings include Home Infusion (IVIG & SCIG) as the primary service, supported by specialized treatment programs for Primary Immunodeficiency, Neuromuscular Disorders (CIDP, GBS, MMN, MG, Dermatomyositis), Dermatological Diseases, IV Antibiotics, and Nutritional Therapy (Parenteral Nutrition). KabaFusion complements its clinical services with the myKabaFusion mobile application for patient care coordination and Telemonitoring for remote patient monitoring. The company serves patients across 45 states through a network of home infusion pharmacies, alternative infusion sites, and home health agencies.

Product and service8 records
1Home Infusion Therapy (IVIG and SCIG)
CategoryHome Infusion Therapy
Description

Specialty home infusion service delivering intravenous (IVIG) and subcutaneous (SCIG) immunoglobulin therapy to adult and pediatric patients with antibody deficiencies and related disorders, dispensed through KabaFusion's network of infusion pharmacies and administered by specialty infusion nurses.

2IV Antibiotic Therapy
CategoryHome Infusion Therapy
Description

Home and ambulatory-site administration of intravenous antibiotics for patients requiring long-term antimicrobial therapy, including complex infections that can be safely managed outside of the hospital under KabaFusion specialty pharmacy oversight.

3Parenteral Nutrition Therapy
CategoryHome Infusion Therapy
Description

Custom-formulated intravenous nutrition therapy delivered to patients in home or ambulatory settings who cannot maintain adequate nutrition through oral or enteral feeding, supported by KabaFusion's specialty pharmacy compounding and clinical monitoring.

4Dermatological Disease Infusion Therapy
CategorySpecialty Infusion Therapy
Description

Condition-specific infusion therapy for patients with dermatological disorders (such as atopic dermatitis), provided via KabaFusion's specialty pharmacy and home/ambulatory infusion services.

5Neuromuscular Disorder Infusion Therapy
CategorySpecialty Infusion Therapy
Description

Condition-specific infusion therapy for patients with neuromuscular disorders, including myasthenia gravis and CIDP, delivered through KabaFusion's home infusion pharmacy and ambulatory infusion suite network.

6Primary Immunodeficiency Infusion Therapy
CategorySpecialty Infusion Therapy
Description

Specialty infusion therapy for patients diagnosed with primary immunodeficiency diseases (PI), including dispensing and home administration of subcutaneous immunoglobulin (SCIG) medications such as CUVITRU, supported by KabaFusion specialty pharmacy and nursing staff.

7myKabaFusion App
CategoryDigital Patient Engagement
Description

Patient-facing mobile application used by home infusion patients to support communication, scheduling, and engagement with KabaFusion's specialty pharmacy and nursing services.

8Telemonitoring
CategoryRemote Patient Monitoring
Description

Remote patient monitoring service paired with home infusion therapy, enabling clinical staff to observe patients during infusions and intervene when needed.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierStrategicTypeTechnology or IntegrationAnnounced on2025-09-10
Description

KabaFusion partnered with Tennr, a healthcare technology company that automates patient processing for referral-based care, to use AI-powered automation and data-driven insights to streamline care coordination, reduce administrative delays in patient onboarding, drive operational efficiencies, and improve patient outcomes. Tennr has raised over $160M from investors including IVP, Andreessen Horowitz (a16z), and Lightspeed Venture Partners.

Strategic tierSignificantTypeStrategic or Co-development PartnerAnnounced on2025-08-19
Description

Memorial Hermann joined existing investors in KabaFusion and will offer home infusion therapy for patients with chronic conditions through the partnership, enhancing access to KabaFusion's services within the Memorial Hermann network.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-05-19
Description

KabaFusion closed a transaction with Coram to acquire 6 pharmacy and ambulatory infusion suite locations, consistent with Coram's previously announced downsizing. This expanded KabaFusion's nationwide footprint of patient-focused services.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-07-30
Description

KabaFusion was selected by GC Biopharma as a Limited Distribution Partner for ALYGLO, an immune globulin subcutaneous treatment for adults with primary humoral immunodeficiency (PI), expanding KabaFusion's portfolio of specialty distribution partnerships.

5Lincare (owned by AdaptHealth)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-04-01
Description

KabaFusion acquired Lincare's infusion pharmacies, expanding its patient-focused home infusion services nationally through strategic acquisition.

kabafusion.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Vivere Health
TypeDirect peer
Description

Specialty home infusion provider focused on IVIG, biologics, and rare disease therapies. Closely comparable mid-market peer competing with KabaFusion in specialty immunoglobulin and chronic condition infusion.

TypeDirect peer
Description

Specialty infusion services provider focused on immunoglobulin, anti-infective, and biologic therapies delivered in home and alternative site settings. Closely comparable mid-sized independent home infusion peer to KabaFusion.

TypeDirect peer
Description

Specialty and home infusion pharmacy offering IVIG, TPN, and chronic disease infusion therapies. A direct competitor to KabaFusion in the home infusion segment with overlapping therapy mix and payor contracts.

TypeEmerging player
Description

Provider of infusion pumps and related clinical services in pain management and post-surgical care. Adjacent peer sharing the home/site-of-care infusion channel but with a different therapeutic focus.

TypeBroad incumbent
Description

CVS Health's home infusion and specialty infusion subsidiary, operating a national network of pharmacies and ambulatory suites. KabaFusion directly acquired 6 Coram locations in 2025 amid Coram's downsizing, evidencing head-to-head overlap.

TypeDirect peer
Description

Largest publicly traded independent home and alternate site infusion services provider in the U.S., offering IVIG, antibiotics, and specialty injectable therapies. Direct competitor to KabaFusion across home infusion and ambulatory infusion suites nationwide.

TypeOthers
Description

Major nonprofit Texas health system and a strategic investor/partner of KabaFusion. Represented as a peer because it is both a customer and an investor, illustrating health-system-owned infusion channels that compete or partner with independent home infusion operators.

TypeDirect peer
Description

Specialty pharmacy integrator focused on embedded hospital outpatient pharmacy and infusion services. Overlaps with KabaFusion in specialty injectable fulfillment and health system partnerships.

TypeBroad incumbent
Description

Specialty and home infusion pharmacy owned by UnitedHealth Group's Optum. Competes with KabaFusion in IVIG and specialty injectable therapy and benefits from payor-aligned patient steering.

TypeDirect peer
Description

Home health and infusion services provider with home infusion pharmacy operations. Competes with KabaFusion for home-based IVIG and antibiotic infusion referrals, especially in the post-acute setting.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Kabafusion, Llc

Home Infusion Therapy Serviceskabafusion.com

KabaFusion is a national home and alternative site infusion provider delivering IVIG, SCIG, IV antibiotics, and parenteral nutrition across 45 states through 33 pharmacies and 21 ambulatory infusion suites, serving adult and pediatric patients with chronic immune, neuromuscular, and dermatological conditions.

What Kabafusion, Llc does

KabaFusion, founded in 2010 by Dr. Sohail Masood, is a national provider of home and alternative site infusion therapy services and operates as the largest privately held home infusion company in the United States. The company specializes in intravenous immunoglobulin (IVIG) and subcutaneous immunoglobulin (SCIG) therapies for chronic conditions — including primary immunodeficiency, neuromuscular disorders (CIDP, GBS, MMN, myasthenia gravis), and dermatological diseases — alongside IV antibiotics, antifungals, and parenteral nutrition. Services are delivered through a network of 33 infusion pharmacies and 21 ambulatory infusion suites licensed across 45 states, supported by specially trained infusion nurses and pharmacists providing 24/7 clinical care. The company employs approximately 2,000 people and holds ACHC and URAC accreditations.

The core technology stack centers on a patient-facing mobile application (myKabaFusion) enabling care team communication, electronic document signing, monthly reordering, and planned telehealth and delivery tracking, complemented by telemonitoring for remote patient oversight. In September 2025, KabaFusion added an AI-powered referral management capability via a strategic partnership with Tennr to automate patient onboarding and reduce administrative friction.

KabaFusion generates revenue primarily through insurance reimbursement (Medicare, Medicaid, and commercial payors) for clinical infusion services and the dispensing of specialty infusion medications, with pricing varying by drug, dose, site of administration, and payor mix. The go-to-market model is sales-led and built on physician referrals, accelerated by rapid coverage verification turnaround and dedicated provider support. Following the February 2026 completion of a approximately $2.2 billion growth investment by Nautic Partners (acquiring from Novo Holdings), the clinician-led management team remains significant investors and continues to lead operations, with stated intent to expand market presence across the U.S. healthcare infusion sector.

Kabafusion, Llc firmographics

Firmographics
Name
Kabafusion, Llc
Legal name
KabaFusion Holdings, LLC
Website
https://kabafusion.com
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
501–1,000 employees
Short description
KabaFusion is a national home and alternative site infusion provider delivering IVIG, SCIG, IV antibiotics, and parenteral nutrition across 45 states through 33 pharmacies and 21 ambulatory infusion suites, serving adult and pediatric patients with chronic immune, neuromuscular, and dermatological conditions.
Ownership category
akta.pro rank

Kabafusion, Llc industry classification

Industry
Product category
Home Infusion Therapy Services
NAICS
All Other Outpatient Care Centers (621498), Other Ambulatory Health Care Services (6219)
SIC
Services-Specialty Outpatient Facilities, Nec (8093)
akta.pro industry
PRIMARYHLAFALAG
Infusion & Home Infusion Pharmacy Services
Healthcare & Life Sciences/Healthcare Providers & Systems/Pharmacy & Medication Management Services
SECONDARYHLAFABAF
Infusion Therapy Centers (Outpatient)
Healthcare & Life Sciences/Healthcare Providers & Systems/Ambulatory & Outpatient Care Centers
SECONDARYHLADAFAG
Home Infusion Therapy & IV Nursing Services
Healthcare & Life Sciences/Elder Care & Long-Term Care/Home Health Care Services (Skilled)
SECONDARYHLAFAEAE
Home Infusion Therapy Providers
SECONDARYHSABACAF
IV Therapy, Infusion & Injection Services (Home-Based)
Home & Personal Services/Elder Care & In-Home Care Services/Skilled Nursing & Clinical Home Health
SECONDARYHLAIACAO
Specialty Injectable & Infusion Therapies (Cross-therapeutic)

Keywords

  • Home infusion therapy
  • Specialty infusion pharmacy
  • IVIG infusion services
  • Ambulatory infusion suites
  • Parenteral nutrition therapy

Where Kabafusion, Llc is headquartered

Location

Headquarters

HQ city
Lexington
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Kabafusion, Llc business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

  1. Home Infusion Therapy Services: KabaFusion generates revenue by providing home and alternative site infusion therapies including IVIG, antibiotics, antifungals, parenteral nutrition, and other specialty medications. Services are reimbursed by insurance payors including Medicare, Medicaid, and commercial insurance. The company serves patients across 45 states through its network of infusion pharmacies and ambulatory infusion suites.
  2. Pharmacy Services and Specialty Medications: Compounding and dispensing specialty infusion medications through licensed pharmacies, with reimbursement through pharmacy benefits.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goInsurance-reimbursed infusion therapy — no publicly listed pricing; costs covered by Medicare, Medicaid, and commercial insurers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Kabafusion, Llc product offering

Product offering

Core offering

KabaFusion operates a national specialty infusion pharmacy platform that provides home and ambulatory-site infusion therapies for patients with chronic and acute conditions. The company dispenses and administers IVIG/SCIG, IV antibiotics, parenteral nutrition, and condition-specific treatments for primary immunodeficiency, neuromuscular disorders, and dermatological diseases across 33 infusion pharmacies and 21 ambulatory infusion suites in 45 states.

Product overview

KabaFusion is a national provider of home and alternative site infusion therapies offering a comprehensive portfolio of services centered around intravenous immunoglobulin (IVIG) and subcutaneous immunoglobulin (SCIG) treatments. The company's core offerings include Home Infusion (IVIG & SCIG) as the primary service, supported by specialized treatment programs for Primary Immunodeficiency, Neuromuscular Disorders (CIDP, GBS, MMN, MG, Dermatomyositis), Dermatological Diseases, IV Antibiotics, and Nutritional Therapy (Parenteral Nutrition). KabaFusion complements its clinical services with the myKabaFusion mobile application for patient care coordination and Telemonitoring for remote patient monitoring. The company serves patients across 45 states through a network of home infusion pharmacies, alternative infusion sites, and home health agencies.

Differentiator

Problem solved

Functional benefit

Products and services

  • Home Infusion Therapy (IVIG and SCIG) Specialty home infusion service delivering intravenous (IVIG) and subcutaneous (SCIG) immunoglobulin therapy to adult and pediatric patients with antibody deficiencies and related disorders, dispensed through KabaFusion's network of infusion pharmacies and administered by specialty infusion nurses.
  • IV Antibiotic Therapy Home and ambulatory-site administration of intravenous antibiotics for patients requiring long-term antimicrobial therapy, including complex infections that can be safely managed outside of the hospital under KabaFusion specialty pharmacy oversight.
  • Parenteral Nutrition Therapy Custom-formulated intravenous nutrition therapy delivered to patients in home or ambulatory settings who cannot maintain adequate nutrition through oral or enteral feeding, supported by KabaFusion's specialty pharmacy compounding and clinical monitoring.
  • Dermatological Disease Infusion Therapy Condition-specific infusion therapy for patients with dermatological disorders (such as atopic dermatitis), provided via KabaFusion's specialty pharmacy and home/ambulatory infusion services.
  • Neuromuscular Disorder Infusion Therapy Condition-specific infusion therapy for patients with neuromuscular disorders, including myasthenia gravis and CIDP, delivered through KabaFusion's home infusion pharmacy and ambulatory infusion suite network.
  • Primary Immunodeficiency Infusion Therapy Specialty infusion therapy for patients diagnosed with primary immunodeficiency diseases (PI), including dispensing and home administration of subcutaneous immunoglobulin (SCIG) medications such as CUVITRU, supported by KabaFusion specialty pharmacy and nursing staff.
  • myKabaFusion App Patient-facing mobile application used by home infusion patients to support communication, scheduling, and engagement with KabaFusion's specialty pharmacy and nursing services.
  • Telemonitoring Remote patient monitoring service paired with home infusion therapy, enabling clinical staff to observe patients during infusions and intervene when needed.

Companies that use Kabafusion, Llc

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Kabafusion, Llc technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature3 records

Kabafusion, Llc partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered strategic, significant, minor and core.

  • TennrstrategicTechnology or Integration · 10 September 2025KabaFusion partnered with Tennr, a healthcare technology company that automates patient processing for referral-based care, to use AI-powered automation and data-driven insights to streamline care coordination, reduce administrative delays in patient onboarding, drive operational efficiencies, and improve patient outcomes. Tennr has raised over $160M from investors including IVP, Andreessen Horowitz (a16z), and Lightspeed Venture Partners.
  • Memorial Hermann Health SystemsignificantStrategic or Co-development Partner · 19 August 2025Memorial Hermann joined existing investors in KabaFusion and will offer home infusion therapy for patients with chronic conditions through the partnership, enhancing access to KabaFusion's services within the Memorial Hermann network.
  • Coram (CVS Health)minorStrategic or Co-development Partner · 19 May 2025KabaFusion closed a transaction with Coram to acquire 6 pharmacy and ambulatory infusion suite locations, consistent with Coram's previously announced downsizing. This expanded KabaFusion's nationwide footprint of patient-focused services.
  • GC Biopharma USA, Inc.coreChannel Partner/ Reseller/ Distributor · 30 July 2024KabaFusion was selected by GC Biopharma as a Limited Distribution Partner for ALYGLO, an immune globulin subcutaneous treatment for adults with primary humoral immunodeficiency (PI), expanding KabaFusion's portfolio of specialty distribution partnerships.
  • Lincare (owned by AdaptHealth)minorStrategic or Co-development Partner · 1 April 2023KabaFusion acquired Lincare's infusion pharmacies, expanding its patient-focused home infusion services nationally through strategic acquisition.

Scale indicators5 records

Recent moves8 records

Expansion highlights6 records

Kabafusion, Llc competitors and assessment

Company assessment

Direct peers

  • Vivere Health: Specialty home infusion provider focused on IVIG, biologics, and rare disease therapies. Closely comparable mid-market peer competing with KabaFusion in specialty immunoglobulin and chronic condition infusion.
  • Soleo Health: Specialty infusion services provider focused on immunoglobulin, anti-infective, and biologic therapies delivered in home and alternative site settings. Closely comparable mid-sized independent home infusion peer to KabaFusion.
  • Amerita (BrightSpring Health Services): Specialty and home infusion pharmacy offering IVIG, TPN, and chronic disease infusion therapies. A direct competitor to KabaFusion in the home infusion segment with overlapping therapy mix and payor contracts.
  • Option Care Health: Largest publicly traded independent home and alternate site infusion services provider in the U.S., offering IVIG, antibiotics, and specialty injectable therapies. Direct competitor to KabaFusion across home infusion and ambulatory infusion suites nationwide.
  • Shields Health Solutions: Specialty pharmacy integrator focused on embedded hospital outpatient pharmacy and infusion services. Overlaps with KabaFusion in specialty injectable fulfillment and health system partnerships.
  • Amedisys Home Infusion: Home health and infusion services provider with home infusion pharmacy operations. Competes with KabaFusion for home-based IVIG and antibiotic infusion referrals, especially in the post-acute setting.

Emerging players

  • InfuSystem Holdings: Provider of infusion pumps and related clinical services in pain management and post-surgical care. Adjacent peer sharing the home/site-of-care infusion channel but with a different therapeutic focus.

Broad incumbents

  • Coram (CVS Health): CVS Health's home infusion and specialty infusion subsidiary, operating a national network of pharmacies and ambulatory suites. KabaFusion directly acquired 6 Coram locations in 2025 amid Coram's downsizing, evidencing head-to-head overlap.
  • Optum Infusion Pharmacy (UnitedHealth/Optum Rx): Specialty and home infusion pharmacy owned by UnitedHealth Group's Optum. Competes with KabaFusion in IVIG and specialty injectable therapy and benefits from payor-aligned patient steering.

Others

  • Memorial Hermann Health System: Major nonprofit Texas health system and a strategic investor/partner of KabaFusion. Represented as a peer because it is both a customer and an investor, illustrating health-system-owned infusion channels that compete or partner with independent home infusion operators.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Kabafusion, Llc compliance and trust

Trust signal

Compliance3 records

Kabafusion, Llc financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Kabafusion, Llc leadership team

Management profile

Number of profiles

Profiles3 records

Kabafusion, Llc funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Kabafusion, Llc M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kabafusion, Llc

What does Kabafusion, Llc do?

KabaFusion operates a national specialty infusion pharmacy platform that provides home and ambulatory-site infusion therapies for patients with chronic and acute conditions. The company dispenses and administers IVIG/SCIG, IV antibiotics, parenteral nutrition, and condition-specific treatments for primary immunodeficiency, neuromuscular disorders, and dermatological diseases across 33 infusion pharmacies and 21 ambulatory infusion suites in 45 states.

Is Kabafusion, Llc a public or private company?

Kabafusion, Llc is a private company. It is classified as private equity controlled and is currently operating.

When was Kabafusion, Llc founded?

Kabafusion, Llc was founded in 2010. It employs 501 to 1,000 people.

Where is Kabafusion, Llc based?

Kabafusion, Llc is headquartered in Lexington, United States, in the North America region.

How does Kabafusion, Llc make money?

Two revenue lines are on record. Home Infusion Therapy Services are the primary driver. The others are pharmacy Services and Specialty Medications.

Who are Kabafusion, Llc's main competitors?

Direct peers on record are Vivere Health, Soleo Health, Amerita (BrightSpring Health Services), Option Care Health, Shields Health Solutions and Amedisys Home Infusion. InfuSystem Holdings is listed as an emerging player. Broad incumbents are Coram (CVS Health) and Optum Infusion Pharmacy (UnitedHealth/Optum Rx). Memorial Hermann Health System is listed as an others.

Does Kabafusion, Llc have an API?

No public API is recorded for Kabafusion, Llc.

What industry is Kabafusion, Llc in?

Kabafusion, Llc's product category is Home Infusion Therapy Services. Its primary akta.pro industry code is HLAFALAG, Infusion & Home Infusion Pharmacy Services, with a secondary code of HLAFABAF, Infusion Therapy Centers (Outpatient). Its NAICS code is 621498 and its SIC code is 8093.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Quiver QuantitativeKabaFusion and CareCloud Partner to Develop AI-Powered LailaCare Platform for Home Infusion Workflow | CCLD Stock NewsKabaFusion and CareCloud announced a partnership to develop LailaCare, an AI-powered platform designed to streamline home infusion workflows including referral intake, eligibility, and revenue cycle management. The initiative aims to reduce administrative burdens and accelerate patient onboarding while allowing KabaFusion's staff to retain control over clinical decisions. CareCloud will design and develop the platform, which will be owned by KabaFusion.GlobeNewswireKabaFusion Selects CareCloud to Build First-of-Its-Kind Platform for Home Infusion and Specialty PharmacyKabaFusion and CareCloud announced a partnership to build LailaCare, an AI-powered platform for home infusion and specialty pharmacy. The platform will unify referral intake, eligibility, patient engagement, and revenue cycle management, with KabaFusion owning it. The project aims to reduce administrative burden and accelerate patient onboarding.Stock TitanCareCloud to Build AI Platform for KabaFusionKabaFusion has partnered with CareCloud to develop LailaCare, an AI-powered platform designed to modernize home infusion and specialty pharmacy workflows. The new system aims to unify operations such as referral intake, eligibility, and revenue cycle management to reduce administrative burdens and accelerate patient onboarding.GlobeNewswireKabaFusion and Nautic Partners Announce Completion of Significant Growth InvestmentNautic Partners completed a growth investment in KabaFusion, with Novo Holdings exiting its stake. KabaFusion, serving 45 states through 33 pharmacies and 21 infusion suites, will use the partnership to expand access to home infusion services. The deal was advised by Goodwin Procter, Houlihan Lokey, and Kirkland & Ellis.Novo HoldingsNovo Holdings · Novo Holdings Closes Sale of KabaFusionNovo Holdings closed the sale of KabaFusion to Nautic Partners. KabaFusion, founded in 2010, serves patients in 45 states through 33 infusion pharmacies and 21 ambulatory suites. The company nearly doubled in size since partnering with Novo Holdings in November 2022.PR NewswireKabaFusion Partners with Tennr to Enhance Patient Outcomes in Home Infusion Care with AI TechnologyKabaFusion and Tennr announced a strategic partnership to use AI to streamline care coordination and improve patient outcomes in home infusion. The collaboration aims to reduce administrative delays and let clinicians focus on direct patient care. Tennr has raised over $160M from investors.GlobeNewswireNovo Holdings Announces Sale of KabaFusionNovo Holdings signed a definitive agreement to exit its investment in KabaFusion, a U.S. home infusion therapy provider. The company, which serves patients in 45 states, has nearly doubled in size since partnering with Novo Holdings in 2022. The transaction is subject to customary closing conditions.GlobeNewswireMemorial Hermann to Offer Home Infusion Therapy for Patients with Chronic ConditionsMemorial Hermann Health System signed a services agreement with KabaFusion to provide home infusion therapy for chronic conditions and IVIG treatment. The partnership expands Memorial Hermann's existing short-term home infusion services to longer-term care. KabaFusion, founded in 2010, offers specialty infusion pharmacy and home nursing support.GlobeNewswireKabaFusion Acquires Infusion Care Assets from Coram® to Expand its Nationwide Footprint of Patient-Focused ServicesKabaFusion closed on acquiring 6 Coram locations, expanding its infusion pharmacy and ambulatory suite network. The deal adds 6 pharmacies and 4 suites, bringing the company to 32 pharmacies and 19 suites across 26 states. KabaFusion is licensed to serve patients in 45 states.GlobeNewswireKabaFusion Selected by GC Biopharma USA, Inc. as a Limited Distribution Partner for Partner of ALYGLO™ for Adults With Primary Humoral Immunodeficiency (PI)KabaFusion was selected by GC Biopharma USA as a limited distribution partner to provide ALYGLO, a 10% immunoglobulin G solution for adults with primary humoral immunodeficiency. The partnership leverages KabaFusion's nationwide IVIG specialty pharmacy services. No further details were disclosed.